Brivanib Metastatic Renal Cell Carcinoma

Summary

This is a phase II study of an investigational agent, brivanib, in patients with refractory metastatic renal cell carcinoma. This study will evaluate the safety and effectiveness of brivanib in renal cell carcinoma, and explore the activity of this drug in this population to determine whether imaging and molecular features of the tumors can be used to predict response. Approximately 30 people with advanced kidney cancer will be enrolled on this study at the University of Pennsylvania.

Timeline

Start

2011-11

Primary completion

2013-09

Completion

2013-09

Outcome

Outcome not reported

Stopped (Enrollment): “In November 2012, this study was permanently closed to new accrual at the request of the drug manufacturer (BMS), who decided not to pursue additional research activity in this patient population.”

Drugs

Indications